GenMont Biotech Inc
TWSE:3164
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
GenMont Biotech Inc
TWSE:3164
|
1.5B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
GenMont Biotech Inc
Glance View
Genmont Biotech Inc. engages in the research of new functional bacteria as well as the manufacturing and sale of probiotic powder. The company is headquartered in Tainan, Tainan. The company went IPO on 2003-06-12. The firm's major products include lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus fermentum, lactobacillus salivarius, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus brevis, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus johnsonii and others. The Company’s products are applied to enhance human immunity against dust allergy and digestive system health care. The firm distributes its products in domestic market and to overseas markets.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for GenMont Biotech Inc is 8.8%, which is below its 3-year median of 12.2%.
Over the last 3 years, GenMont Biotech Inc’s Net Margin has decreased from 22.9% to 8.8%. During this period, it reached a low of 4% on Jun 30, 2025 and a high of 22.9% on Aug 30, 2022.
